Recursion
@recursionpharma.bsky.social
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here. Learn more at recursion.com #techbio
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
November 12, 2025 at 2:47 PM
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
November 10, 2025 at 2:22 PM
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
November 6, 2025 at 3:34 PM
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
October 15, 2025 at 2:23 PM
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪
October 13, 2025 at 3:24 PM
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
October 6, 2025 at 1:49 PM
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
October 2, 2025 at 1:34 PM
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
We♥️our innovators.
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
September 22, 2025 at 1:48 PM
We♥️our innovators.
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
September 18, 2025 at 1:29 PM
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...
👉 event.webcasts.com/viewer/event...
September 16, 2025 at 2:15 PM
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...
👉 event.webcasts.com/viewer/event...
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...
👉 www.ft.com/content/9a8a...
September 15, 2025 at 2:41 PM
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...
👉 www.ft.com/content/9a8a...
🌄 The peak is now the basecamp.
A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
September 11, 2025 at 3:07 PM
🌄 The peak is now the basecamp.
A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social),
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell
👉Read more: insights.citeline.com/in-vivo/lead...
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell
👉Read more: insights.citeline.com/in-vivo/lead...
September 5, 2025 at 1:45 PM
🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social),
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell
👉Read more: insights.citeline.com/in-vivo/lead...
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell
👉Read more: insights.citeline.com/in-vivo/lead...
📣 The inaugural episode of TechBio Talks is now live!
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...
September 4, 2025 at 1:20 PM
📣 The inaugural episode of TechBio Talks is now live!
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...
🔹 Join us in September as Recursion executives present at two upcoming investor conferences:
▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference
▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference
👉 Learn more and tune in here: ir.recursion.com.
#investor #IR #IRconference
▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference
▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference
👉 Learn more and tune in here: ir.recursion.com.
#investor #IR #IRconference
August 27, 2025 at 1:10 PM
🔹 Join us in September as Recursion executives present at two upcoming investor conferences:
▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference
▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference
👉 Learn more and tune in here: ir.recursion.com.
#investor #IR #IRconference
▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference
▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference
👉 Learn more and tune in here: ir.recursion.com.
#investor #IR #IRconference
🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
August 26, 2025 at 1:13 PM
🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.
August 22, 2025 at 1:17 PM
🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
August 19, 2025 at 2:31 PM
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
💡 “It’s not a taller ladder, it’s an elevator.”
In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
August 8, 2025 at 3:18 PM
💡 “It’s not a taller ladder, it’s an elevator.”
In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...
August 4, 2025 at 3:13 PM
Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...
🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio
August 1, 2025 at 2:03 PM
🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio
At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio
July 30, 2025 at 1:31 PM
At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio
Join our (L)earnings Call on Tuesday, August 5.
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.
👉 Submit questions: forms.gle/ciFX2KbLfkAv...
👉 Read more: ir.recursion.com/news-release...
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.
👉 Submit questions: forms.gle/ciFX2KbLfkAv...
👉 Read more: ir.recursion.com/news-release...
July 29, 2025 at 12:17 PM
Join our (L)earnings Call on Tuesday, August 5.
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.
👉 Submit questions: forms.gle/ciFX2KbLfkAv...
👉 Read more: ir.recursion.com/news-release...
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.
👉 Submit questions: forms.gle/ciFX2KbLfkAv...
👉 Read more: ir.recursion.com/news-release...
“How do we tap the potential in these data sets that can truly unlock better trials for patients, reduce timelines, and improve the patient experience?” - Sid Jain, SVP of clinical development and data science at Recursion, in a new article in Clinical Leader. www.clinicalleader.com/doc/clinical...
July 25, 2025 at 1:52 PM
“How do we tap the potential in these data sets that can truly unlock better trials for patients, reduce timelines, and improve the patient experience?” - Sid Jain, SVP of clinical development and data science at Recursion, in a new article in Clinical Leader. www.clinicalleader.com/doc/clinical...